



EVITRADE Announces Binding LOI with Western Agri Supply Solutions

VANCOUVER, BC, Thursday September 27, 2018 – EVITRADE Health Systems Corp. (CSE:EVA, OTCQB: EVAHF) (the “Company” or “EVITRADE”) announces the agreement of terms for a binding letter of intent (“LOI”) with Western Agri Supply Solutions Corp. (“WASSC”). WASSC is an agricultural supply company that is in the business of supply sourcing and supply-chain management in the industrial Hemp markets.

“We look forward to working with WASSC to manage our own supply-chain for biomass to help control pricing, product quality and ultimately margins for the company” said C.K. Cheung.

The LOI with Western Agri Supply Solutions Corp. is pursuant to Evitrade completing additional due diligence with WASSC to and to complete the transaction (the “Proposed Transaction”) whereby Evitrade will acquire all of the outstanding share of WASSC in exchange for an aggregate of up to 20,000,000 shares of Evitrade issued at the deemed price of \$0.30 per share. The result of the Proposed Transaction would be that WASSC would become a wholly-owned subsidiary of Evitrade.

Management continues to strive to seek optimal business and commercialization strategies for the Company. Full details of the transaction will be available subsequent to closing on the definitive agreement.

Contact: C.K. Cheung, CEO & Director

EVITRADE Health Systems Corporation
(formerly Auxellence Health Corporation)

Email info@evahealthsystems.com

Website <http://www.evahealthsystems.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>

US OTC Markets: <http://www.otcm Markets.com/stock/EVAHF/news>



About EVITRADE Health (CSE: EVA, OTCQB: EVAHF)

EVITRADE Health Systems Corp. (formerly Auxellence Health Corp.), is a Technology company specializing in the Life Sciences sector looking to deliver effective health solutions with a higher degree of predictability and consistency.

The Company is focused in four main areas, Autonomous Medical Care, Molecular Biology, Nutraceutical Solutions and Genetic Selection. Through its Focus on Autonomous Medical Care, the Company offers a physiologically interactive computing platform that integrates medical devices and artificial intelligence applications into a fully automated, personal health management system for hypertension, arrhythmia, diabetes, and obesity.

Disclaimers – Forward Looking Statements

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>, and <http://www.otcm Markets.com/stock/AXHMF/filings>. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.